Foresee Pharmaceuticals Co., Ltd. announced the appointment of Susan Shelby as Sr. Vice President of Clinical Development and Program Lead /Sr. Vice President of Global Clinical Operations, Biomedical Systems in place of Yisheng Lee, Chief Medical Officer and Wenjin Yang/Chief Scientific Officer (Co-Acting Head of Clinical Development). The effective date is January 10, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
83.8 TWD | +0.72% |
|
+0.24% | -12.89% |
06-24 | Foresee Pharmaceuticals Co., Ltd. announced a financing transaction | CI |
05-14 | Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.89% | 346M | |
+22.30% | 47.96B | |
+0.83% | 42.45B | |
+43.91% | 41.47B | |
+27.04% | 31.6B | |
+21.26% | 28.63B | |
-4.47% | 28.03B | |
+52.55% | 14.56B | |
+44.78% | 14.14B | |
+3.05% | 12.58B |
- Stock Market
- Equities
- 6576 Stock
- News Foresee Pharmaceuticals Co., Ltd.
- Foresee Pharmaceuticals Co., Ltd. Announces Board Changes, Effective from January 10, 2022